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a b s t r a c t 
Background: Routine clinical culture detects a subset of the cystic fibrosis (CF) airways microbiota based
on culture-independent (molecular) methods. This study aimed to determine how extended sputum cul- 
ture of viable bacteria changes over time in relation to clinical status and predicts exacerbations.
Methods: Sputa from patients at a baseline stable and up to three subsequent time-points were analysed
by extended-quantitative culture; aerobe/anaerobe densities, ecological indexes and community structure
were assessed together with clinical outcomes.
Results: Eighty patients were prospectively recruited. Sputa were successfully collected and cultured at
199/267 (74.5%) study visits. Eighty-two sputa from 25 patients comprised a complete sample-set for
longitudinal analyses. Bacterial density, ecological indexes and clinical outcomes were unchanged in 18
patients with three sequential stable visits. Conversely, in 7 patients who had an exacerbation, total bac- 
terial and aerobe densities differed over four study visits ( P < .001) with this difference particularly appar- 
ent between the baseline visit and completion of acute antibiotic treatment where a decrease in density
was observed. Bacterial communities were more similar within than between patients but stable patients
had the least variation in community structure over time. Using logistic regression in a further analysis,
baseline features in 37 patients without compared to 15 patients with a subsequent exacerbation showed
that clinical measures rather than bacterial density or ecological indexes were independent predictors of
an exacerbation.
Conclusions: Greater fluctuation in the viable bacterial community during treatment of an exacerbation
than between stable visits was observed. Extended-quantitative culture did not provide prognostic infor- 
mation of a future exacerbation.∗ Corresponding author at: School of Pharmacy, Queen’s University Belfast,
Belfast, UK
E-mail address: l.sherrard@qub.ac.uk (L.J. Sherrard).
1 LJS and GGE are joint first authors on this paper.










Chronic infection of the lower airways is the major cause of
orbidity and reduced survival in people with cystic fibrosis (CF)
 1 ]. Clinical microbiological laboratories routinely determine the
resence of recognised CF pathogens in respiratory secretions us-
ng a combination of nonselective and selective agars [ 2 ]. In-
ormation from routine culture is used by physicians to guide




















































































































a  nalyses, which provide more in-depth analysis of the CF airway
acterial community composition and structure, have shown that
educed community diversity and increased dominance by a recog-
ised pathogen, is associated with increasing age, greater antibi-
tic use, lower lung function and disease progression [ 3–5 ]. Both
linical microbiological and culture-independent techniques have
een used to determine whether changes in the bacterial density
r community underpin the aetiology of pulmonary exacerbations
r are associated with their onset or future risk [ 6–8 ]. 
Not all bacteria, especially so-called “commensal” respiratory
ora, are cultured using standard clinical culture protocols. In con-
rast, culture-independent studies may include genomic DNA from
on-viable cells, which can impact analyses of the bacterial com-
unity. Extended-quantitative culture is an alternative method to
ssess respiratory secretions, similar in methodology to routine
ulture, but more comprehensively targeting the growth and quan-
ity of bacteria, including facultative and obligate anaerobes. This
ethod, therefore, can be used to assess the bacterial community
nalogous to culture-independent methods from an ecological per-
pective but with the added benefit of only detecting viable bacte-
ia [ 9–12 ]. 
In this study, extended-quantitative culture of prospectively col-
ected sputum was used to investigate the lower airway bacterial
ommunity of people with CF, an approach in which the abun-
ance of individual cultured taxa is assessed as a proportion of
he total number of colony-forming units obtained for each spu-
um sample. We hypothesised that extended-quantitative culture
ould (1) demonstrate conserved bacterial density and communi-
ies in clinically stable disease; (2) detect temporal changes in bac-
erial density and communities during a pulmonary exacerbation;
nd (3) predict a future pulmonary exacerbation. 
. Methods
.1. Participants 
Patients diagnosed with CF [ 13 ] were recruited during routine
utpatient appointments at the paediatric and adult CF Centres
f the Belfast Health and Social Care Trust (Royal Belfast Hospi-
al for Sick Children and Belfast City Hospital). Written informed
onsent/assent was obtained. The study was approved by the Of-
ce for Research Ethics Committees Northern Ireland (10/NIR01/41)
nd co-sponsored by the Belfast Health and Social Care Trust and
ueen’s University Belfast (10067SE-OPMS). Cross-sectional stud- 
es involving patients recruited at study enrolment are published
 12 , 14–16 ]. 
.2. Study visits and target sample collection 
Spontaneously expectorated sputum was collected at study en-
olment (‘Baseline’) when patients were clinically stable which
as defined as no requirement for intravenous or additional in-
aled/oral antibiotics for respiratory symptoms in the prior 4-
eeks. Up to two further consecutive stable samples (‘S2’ and ‘S3’)
ere collected from patients who remained clinically stable (no re-
uirement for intravenous antibiotics) for the study duration when
hey attended outpatient appointments. For patients who subse-
uently presented with an exacerbation [ 17 ], sputum was collected
t initiation of (‘PEx1’; 24 h before to a maximum of 48 h after the
rst dose of intravenous antibiotics) and at completion of (‘PEx2’;
4 h before to a maximum of 48 h after last dose of intravenous
ntibiotics) treatment [ 9 ]. Another sample was collected post-PEx2
hen the patient had recovered and was clinically stable at outpa-
ient review (‘Follow-up’). .3. Extended-quantitative culture 
Comprehensive details are provided in the supplementary file.
riefly, samples were immediately placed into an anaerobic pouch
AnaeroGen TM COMPACT, Oxoid Limited, Hampshire, UK) and pro-
essed within an anaerobic cabinet. Quantitative culture was per-
ormed and the total viable count (TVC; colony forming units per
ram of sputum [CFU/g]) of all distinct colony morphologies were
numerated and identified to the genus-level using near full-length
6S rRNA sequencing. 
.4. Clinical characteristics 
Age, gender, body mass index (BMI), spirometry with percent
redicted calculated using reference ranges for all ages [ 18 , 19 ],
o-morbidities and qualitative routine culture results were ob-
ained. No patients had a history of non-tuberculous mycobacte-
ia (NTM) infection at enrolment to the study nor became NTM-
ositive during the study period. Treatments received in the pre-
ious month or additional medications to treat an exacerbation
ere recorded. No patients received cystic fibrosis transmembrane
onductance regulator (CFTR) modulators during the study period.
n age-appropriate version of the Cystic Fibrosis Questionnaire-
evised (CFQ-R) was used to report outcomes at Baseline [ 20 ].
FTR function was recorded from the genotype [ 21 ]. 
.5. Analyses 
Analyses were generated using IBM SPSS (v22) and the R
nvironment ( http://www.r-project.org ). P < .05 was considered
tatistically significant. Ecological indexes commonly used to
haracterise community composition and structure in various
atural environments, including human disease, were calculated:
ichness (number of counted taxa); dominance; evenness; commu-
ity diversity (Shannon-Wiener index [H ′ ] combining community
ichness and evenness). Bacterial community structures were
ompared using the Bray-Curtis quantitative index of dissimilar-
ty. Continuous variables were analysed using a Student’s t -test,
ann-Whitney U test, repeated measures analysis of variance
ANOVA) or Friedman’s test. Categorical variables were compared
sing Pearson’s chi-square/Fisher’s exact test. Logistic regression
as performed to identify predictors of a future pulmonary ex-
cerbation within 4-months of Baseline [ 22 ]. This time-frame
eflects the median time between outpatient appointments, when
linically stable. Further details are provided in the supplementary
le. 
. Results
.1. Study overview: visits and patients 
A total of 267 study visits occurred in 80 patients. Sputa
 n = 199; 74.5% of study visits) were successfully collected and cul-
ured at least once from all patients. For the remaining study visits
 n = 68), there was an insufficient volume of sputum for extended-
uantitative culture ( n = 53) or the patient was unable to expecto-
ate ( n = 15). The majority of these visits ( n = 4 9/6 8; 72.1%) were
hen patients were clinically stable. 
Characteristics of children (6–18 years, n = 10) and adults
 ≥18 years, n = 70) at study enrolment are provided in Table 1 .
ig. 1 shows how patients were selected to address the three
tudy hypotheses. Thirty-five patients were treated for ≥1 ex-
cerbation. Intravenous antibiotics were administered to all pa-
ients with additional oral antibiotics prescribed to treat nine ex-
cerbations. Dual intravenous antibiotic therapy with tobramycin
Table 1
Overview of characteristics of children and adults at study enrolment.
Variable 6–18 years ≥18 years P -value
( n = 10) ( n = 70) 
Age, mean ( ±sd) 13.2 (2.9) 31.9 (12.4) NA
Gender; female, number
(%)
3 (30.0) 29 (41.4) .7
FEV 1 % predicted, mean
( ±sd) a 
81.4 (11.7) 65.1 (20.5) .02
BMI (kg/m 2 ), mean
( ±sd) a 
19.3 (2.8) 23.5 (4.1) .002
Diagnoses, number (%)
Pancreatic insufficient 7 (70.0) 61 (87.1) .2
Cystic fibrosis-related
diabetes
0 (0) 9 (12.9) .6
Liver disease 0 (0) 3 (4.3) 1.0
CFTR function, number
(%)
Minimal 7 (80.0) 42 (60.0)
Residual 0 (0) 22 (31.4) .03
Non-classified 3 (3.0) 6 (8.6)
CFQ-R (scores from 0 to 100), median (range) a
Respiratory domain 
score
61.2 (8.3–83.3) 66.7 (0.0–88.9) c .3
Emotional domain score 73.4 (41.7–100.0) 80.0 (0.0–100.0) c .6
Routine bacterial culture b , number positive (%)
Pseudomonas aeruginosa 4 (40.0) 35 (51.5) .7
MSSA 6 (60.0) 17 (25.0) .06
MRSA 2 (20.0) 3 (4.4) .1
Haemophilus influenzae 1 (10.0) 0 (0) .1
Stenotrophomonas
maltophilia
3 (30.0) 5 (7.4) .06
Achromobacter spp. 0 (0) 2 (2.9) 1.0
Burkholderia cepacia
complex
0 (0) 9 (13.2) .6
Chronic treatments prescribed, number (%)
Oral azithromycin 2 (20.0) 45 (64.3) .01
Inhaled antibiotics 4 (40.0) 41 (58.6) .3
Oral flucloxacillin 6 (60.0) 2 (2.9) < .001
DNase 9 (90.0) 47 (67.1) .3
Hypertonic saline 1 (10.0) 14 (20.0) .7
Insulin 0 (0) 6 (8.6) 1.0
Antacid 1 (10.0) 31 (44.3) .05
FEV 1 % predicted, forced expiratory volume in the first second percent predicted;
BMI, body mass index, CFTR, cystic fibrosis transmembrane conductance regulator
(Definitions of CFTR function: residual function, harbouring ≥1 allele with Class IV- 
V mutations; minimal function, harbouring two alleles with Class I-III mutations;
non-classified, harbouring two alleles with mutations of unknown function); CFQ- 
R, Cystic Fibrosis Questionnaire revised (a higher score indicates a higher patient- 
reported quality of life with regard to respiratory and emotional status); MSSA,
methicillin-susceptible Staphylococcus aureus ; MRSA, methicillin-resistant Staphylo- 
coccus aureus ; NA, non-applicable.
a Two people were excluded as they were recruited on the same day that treat- 
ment of a pulmonary exacerbation was subsequently started.
b Data not available for two adult patients; c Two adults did not complete the








































































(  and piperacillin/tazobactam ( n = 8) was most common. The me-
dian (range) length of time between PEx1 and PEx2 was 0.5 (0.2–2)
months. The Follow-up sample was collected a median (range) of
2 (1-10) months post-PEx2. 
3.2. Detection of bacteria 
Bacteria were cultured in 199 sputum samples and taxa were
classed confidently to the genus-level. Consensus of species iden-
tity could not be reached using different reference sequence
databases for some taxa, such as a number of streptococci, which
have a high sequence similarity. This precluded analysis to the
species-level. Aerobic ( n = 37) and obligate anaerobic ( n = 23) gen-
era were identified with 10/60 (16.7%) genera found in > 25% ofamples (Table S1). Multiple genera were found in all samples with
 median (range) of 7 (2–12) organisms. In > 50% of positive sam-
les, the majority of detected genera were present at ≥1.0 × 10 4 
FU/g. 
.3. Identification of cohorts to address hypotheses 1 & 2 
Eighty-two sputa from 25 patients comprised a complete
ample-set for longitudinal analyses. These patients had similar
linical characteristics to those who were excluded ( n = 55) from
hese analyses (Table S2). 
There were 18 patients who provided three consecutive spu-
um samples that were sufficient for extended-quantitative culture
Baseline, S2, S3; Fig. 1 ) and remained clinically stable during the
tudy. The median (range) time between first and third samples in
his “clinically stable disease” cohort was ~8 (6-16) months. There
ere also seven patients who provided four consecutive sputum
amples sufficient for extended-quantitative culture before, dur-
ng and after an exacerbation (Baseline, PEx1, PEx2, Follow-up;
ig. 1 ). This “pulmonary exacerbation cohort” was treated with in-
ravenous antibiotics with additional oral antibiotics prescribed for
wo patients (Fig. S1). 
Baseline characteristics were similar between the cohorts (Ta-
le S3). Mean [ ±sd] lung function was higher in the clinically sta-
le disease cohort (70.1 [23.2] % predicted) compared to the pul-
onary exacerbation cohort (51.0 [19.9] % predicted) but this was
ot statistically significant ( P = .06) (Table S3). No statistically sig-
ificant changes were detected longitudinally for FEV 1 % predicted
r BMI in those with stable disease ( Table 2 ). Lung function (but
ot BMI) fluctuated within the pulmonary exacerbation cohort. At
Ex1 there was a mean ( ±sd) decrease of 12.3 (15.6) % in lung
unction compared with Baseline. At PEx2 and Follow-up, there
as a mean ( ±sd) increase of 14.4 (22.7) % and 8.5 (21.4) % com-
ared to Baseline, respectively. This was not statistically significant
 P = .07; Table 2 ). 
Most patients were chronically infected with ≥1 recognised
athogen by routine culture ( n = 19/25, 76.0%) (Table S3) [ 23 ]. The
linically stable disease cohort had lower rates of chronic Pseu-
omonas aeruginosa infection ( n = 10/18; 55.6%) compared to the
ulmonary exacerbation cohort ( n = 6/7, 85.7%) ( Fig. 2 A and Fig.
1). Pseudomonas , however, was not always the dominant taxa iso-
ated in patients with P. aeruginosa infection. For example, in pa-
ient B002, Pseudomonas TVC comprised only 0.03–0.12% of the
ommunity ( Fig. 2 A). 
.4. Hypothesis 1: bacterial communities in clinically stable disease 
To address our first hypothesis that extended-quantitative cul-
ure could demonstrate conserved bacterial density and communi-
ies in clinically stable disease, bacterial communities were anal-
sed in the clinically stable disease cohort ( Fig. 1 ). 
No statistical differences in TVCs or ecological indexes ( Table 2 ),
n sputum were observed in longitudinal stable subject samples. 
Although the occurrence and relative abundance of bacterial
enera fluctuated longitudinally and differed between patients ( Fig.
 A), principle components analysis (PCA) indicated that within-
atient bacterial communities were very similar in most patients
s shown by the closeness of the points on the plot (e.g. B026,
063, B156) ( Fig. 2 B(i)). However, four patients (B018, B050, B067,
099) had one of three sputum community structures that clus-
ered more closely with other patient samples than to their other
wo, based on bifurcation of major branches ( Fig. 2 C). Shifts in
putum community structure occurred at each study visit for only
ne patient (B098) ( Fig. 2 C). Overall, significant similarities within-
atients were observed which explained ~70% of the variation
R 2 = 0.70; P = .001; Analysis of variance using distance matrices
Fig. 1. Patient stratification to test three study hypotheses: extended-quantitative culture could (1) demonstrate conserved bacterial density and communities in clinically
stable disease (2) detect temporal changes in bacterial density and communities during a pulmonary exacerbation and (3) predict a future pulmonary exacerbation. De- 
scription of samples: Baseline, sputum collected when clinically stable; S2, sputum collected at second clinically stable visit; S3, sputum collected at third clinically stable
visit; PEx1, sputum collected at the initiation of treatment of a pulmonary exacerbation; PEx2, sputum collected at completion of treatment of a pulmonary exacerbation;




































w  ermutational multivariate [adonis]; 999 permutations). Moreover,
acterial community structures between study visits ( Fig. 2 B (ii))
ere more variable compared to within-patient samples ( Fig. 2 B
i)), demonstrated by greater distance between points on the for-
er plot. However, a permutation test using the Bray-Curtis dis-
imilarity measures for homogeneity of multivariate dispersion,
howed no significant difference ( P = .481; 999 permutations) (Fig.
2A (i) and (ii)). 
.5. Hypothesis 2: bacterial communities during pulmonary 
xacerbations 
To address our second hypothesis that extended-quantitative
ulture could detect temporal changes in bacterial density and
ommunities during a pulmonary exacerbation, the pulmonary ex-
cerbation cohort was analysed ( Fig. 1 and Fig. S1). 
Total bacterial density ( P < .001) and density of aerobes
 P < .001), but not obligate anaerobes ( P = .1), differed significantly
ver time ( Table 2 ). Post-hoc analysis showed that statistical differ-nces in TVCs of total bacteria were not detected between Baseline
s PEx1 ( P = .8) but were detected for Baseline vs PEx2 ( P = .004)
nd PEx1 vs PEx2 ( P = .007) whilst differences in aerobic TVCs oc-
urred between Baseline vs PEx2 ( P = .02) (Table S4). TVCs of 6/10
ost prevalent aerobic ( Streptococcus , Rothia , Actinomyces , Pseu-
omonas , Gemella ) and obligate anaerobic ( Prevotella ) genera de-
reased sequentially between Baseline and PEx2; however, TVCs
ad increased again by Follow-up (Fig. S3). There were no statis-
ically significant fluctuations in ecological indexes ( Table 2 ). 
PCA demonstrated that bacterial community structures were
ariable within-patients( Fig. 3 A(i)) and a within-patient shift in
putum community structure occurred for all individuals for at
east one study visit based on divergence of major branches ( Fig.
 B). It was noted that some patients experienced a substantial shift
n their bacterial community structure between Baseline and PEx1
B014, B019, B023, B034, B203) whilst communities in other pa-
ients remained relatively unchanged (B0 04, B0 08) ( Fig. 3 B). How-
ver, significant similarities within-patients were still observed,
hich explained ~34% of the variation (R 2 = 0.34; P = .008; adonis;
Table 2
Longitudinal change in the geometric mean bacterial total viable count and ecological indexes in sputum and clinical parameters of the clinically stable disease ( n = 18) 
and pulmonary exacerbation ( n = 7) cohorts to address hypotheses 1 & 2. 
Clinically stable disease cohort P -value Pulmonary exacerbation cohort P -value
Baseline S2 S3 Baseline PEx1 PEx2 Follow-up
CFU/g, geometric mean (95% CI)
Total 5.2 × 10 7 (2.0 ×
10 7 –1.3 × 10 8 )
5.6 × 10 7 (2.8 ×
10 7 –1.2 × 10 8 )
4.4 × 10 7 (2.5 ×
10 7 –7.8 × 10 7 )
.7 2.0 × 10 8 (7.8 ×
10 7 –5.5 × 10 8 )
7.1 × 10 7 (1.3 ×
10 7 –4.0 × 10 8 )
2.5 × 10 6 (7.1 ×
10 5 –9.1 × 10 6 )
3.7 × 10 7 (9.8 ×
10 6 –1.4 × 10 8 )
< .001 ∗
Aerobe 4.6 × 10 7 (1.9 ×
10 7 –1.1 × 10 8 )
5.4 × 10 7 (2.6 ×
10 7 –1.1 × 10 8 )
3.4 × 10 7 (1.9 ×
10 7 –6.3 × 10 7 )
.4 1.9 × 10 8 (7.1 ×
10 7 –5.0 × 10 8 )
6.8 × 10 7 (1.2 ×
10 7 –3.9 × 10 8 )
1.0 × 10 6 (1.0 ×
10 5 –1.0 × 10 7 )
3.4 × 10 7 (8.5 ×




2.7 × 10 4 (8.7 ×
10 2 –8.3 × 10 5 )
2.0 × 10 5 (1.1 ×
10 4 –3.9 × 10 6 )
2.0 × 10 5 (9.5 ×
10 3 –4.1 × 10 6 )
.3 5.5 × 10 5 (1.7 ×
10 3 –1.8 × 10 8 )
1.2 × 10 6 (3.2 ×
10 5 –4.7 × 10 6 )
1.4 × 10 3 (2.3 ×
10 0 –8.7 × 10 5 )
1.1 × 10 6 (1.5 ×
10 5 –8.7 × 10 6 )
.1
Ecological indexes, median (range)
Richness 7 (3 −12) 8 (4–12) 8 (2 −10) .5 7 (3–9) 6 (5–8) 5 (2–7) 7 (5–8) .2
Dominance 0.5 (0.2–1.0) 0.4 (0.2–0.9) 0.4 (0.2–1.0) .7 0.5 (0.4–1.0) 0.5 (0.3–0.8) 0.6 (0.3–1.0) 0.5 (0.3–0.9) 1.0
Diversity 0.9 (0.09–1.7) 1.1 (0.3–1.7) 1.2 (0.07–1.9) .6 1.0 (0.08–1.1) 0.9 (0.5–1.5) 0.8 (0.02–1.3) 1.0 (0.3–1.4) .7
Evenness 0.4 (0.2–0.7) 0.4 (0.1–0.6) 0.5 (0.1–0.7) .3 0.3 (0.2–0.5) 0.4 (0.3–0.7) 0.5 (0.2–0.7) 0.5 (0.3–0.5) .07
Clinical parameter, mean ( ±sd)
FEV 1 %
predicted
70.1 (23.2) 68.7 (21.1) 70.8 (22.9) .5 51.0 (19.9) 45.0 (20.1) 59.4 (26.6) 56.9 (26.2) .07
BMI, kg/m 2 23.0 (2.6) 23.0 (2.4) 23.3 (3.1) .5 22.0 (3.0) 21.7 (3.1) 21.7 (3.0) 22.0 (3.0) .1
CFU/g, colony-forming units per gram of sputum; CI, confidence interval; FEV 1 % predicted, forced expiratory volume in the first second percent predicted; BMI, body mass
index.
Description of samples: Baseline, sputum collected when clinically stable; S2, sputum collected at second clinically stable visit; S3, sputum collected at third clinically stable
visit; PEx1, sputum collected at the initiation of treatment of a pulmonary exacerbation; PEx2, sputum collected at completion of treatment of a pulmonary exacerbation;
Follow-up, sputum collected when clinically stable post exacerbation.
BMI comparison: clinically stable disease cohort, n = 17; pulmonary exacerbation cohort, n = 5. 
∗ Statistical difference between timepoints identified using a repeated measures ANOVA with post-hoc analysis showing that statistical differences in TVCs of total
bacteria were detected between Baseline and PEx2 (P = .004) and PEx1 and PEx2 (P = .007) whilst differences in aerobic TVCs occurred between Baseline and PEx2 (P = .02) 






























































999 permutations). PCA indicated that bacterial community struc-
tures were variable between study visits ( Fig. 3 A(ii)) and a permu-
tation test using the Bray-Curtis dissimilarity measures for homo-
geneity of multivariate dispersion showed a significant dissimilar-
ity in community structures over time, with the largest proportion
of the variance driven by changes in the community composition
at PEx2 ( P = .004; 999 permutations) (Fig. S2B (i) and (ii)). 
3.6. Hypothesis 3: prediction of a pulmonary exacerbation 
To address our third hypothesis that extended-quantitative cul-
ture could predict a future exacerbation, data were analysed from
52 eligible patients ( Fig. 1 ). Patients were stratified depending on
whether they had an exacerbation within 4-months of Baseline
( n = 15) or remained clinically stable ( n = 37). 
In univariable logistic regressions (Table S5), higher lung func-
tion (odds ratio [OR], 0.95; 95% confidence interval [CI], 0.91–0.98;
P = .004) and BMI (OR, 0.80; 95% CI, 0.65–0.99; P = .04) were sig-
nificantly associated with reduced odds of a future exacerbation.
Female gender (OR, 3.09; 95% CI, 0.89–10.74; P = .08) and chronic
azithromycin treatment (OR, 4.22; 95% CI, 1.02–17.47; P = .05) were
associated with an elevated, but non-significant, odds of a future
exacerbation whilst a better CFQ-R respiratory symptom score was
associated with a reduced, but non-significant, odds (OR, 0.96;
95% CI, 0.92–1.01; P = .09). After controlling for all these factors
in a multivariable logistic regression, lung function ( P = .01), BMI
( P = .02) and respiratory symptom score ( P = .03) remained statisti-
cally significant (Table S5). The future likelihood of an exacerbation
reduced as lung function (OR, 0.91; 95% CI, 0.85–0.98), BMI (OR,
0.61; 95% CI, 0.40–0.93) or CFR-Q respiratory score (OR, 0.92; 95%
CI, 0.85–0.99) increased. None of the extended-quantitative culture
variables (TVCs and ecological indexes) were independent predic-
tors of an exacerbation in this cohort. . Discussion
This study describes extended-quantitative culture analysis of
F lower airway communities during both clinically stable disease
nd pulmonary exacerbation and begins to address if extended-
uantitative culture provides further information with respect to
linical outcomes. A key study strength is that patients were fol-
owed prospectively and were stratified according to their clin-
cal course during the study period. Bacterial community struc-
ures were more similar within than between patients and those
ith stable disease had more conserved bacterial communities
ongitudinally compared to those who had an exacerbation. Most
ther studies investigating the lower airway dynamics are primar-
ly based on molecular analysis of samples [ 5–9 ]. Our findings
omplement those studies and confirmed that a complex bacte-
ial community exists. However, a further strength of our study is
hat we have provided key information on the viability and den-
ity of the bacteria identified, which cannot be accurately deter-
ined using next-generation sequencing analyses. Despite the re-
overy and quantification of a large number of potentially rele-
ant taxa and assessment of the viable lower airway ecology, the
xtended-quantitative culture variables did not predict an exacer-
ation which might limit the potential prognostic applicability of
he method to clinical practice. 
Most patients who remained clinically stable throughout the
ampling period were chronically infected with a CF pathogen
nd demonstrated conserved bacterial densities and ecological in-
exes. However, fluctuations in the community structure were
ound in five patients ( Fig. 2 C) without any change in clinical sta-
us or intravenous antibiotic treatment; three of these patients
ad different CF pathogens detected at one time-point by rou-
ine culture (B018, B067, B098). The latter finding supports clini-
al guidelines which recommend that CF respiratory samples are
ultured at every clinic visit to identify new pathogens as early as























Prior culture-independent studies found limited within-patient
hanges in the bacterial load and/or diversity measures between
tability and during treatment of an exacerbation while others re-
orted that significant changes occurred [ 3 , 5 , 6 ]. In our study, bac-
erial community composition and treatment regimens for exac-
rbations were individual but a temporal reduction in the bacte-ig. 2. Clinically stable disease cohort ( n = 18; hypothesis 1). A. The temporal variation in
hown. Other genera detected (found in a relative abundance of < 5% in all samples): Aes
erium , Dermacoccus , Enterococcus , Escherichia , Granulicatella , Leptotrichia , Moraxella , Neisse
ndividual patients, with different coloured points (samples) indicating the study visit or 
onent (PC1) accounts for most of the data variability. The proximity of the points on t
ommunities being closer together. Elipses indicate 95% confidence intervals. PC2, second
unity structure (bacterial membership [CFU/g]) of sputum samples according to the Bra
tructures are shown by different coloured boxes (labelled 1–5). Bifurcation of clusters ind
ng dissimilarity. Description of samples: Baseline, sputum collected when clinically stable;
linically stable visit.ial density was found not at the inception of treatment of the
xacerbation (PEx1) but during antimicrobial therapies for exacer-
ation (PEx2) before returning to pre-treatment levels at review.
ost of the variation was, therefore, likely to be driven by treat-
ent. A similar pattern was observed for the density of some of
he most common genera (Fig. S3) identified suggesting resilience the relative abundance of genera detected (based on CFU/g) within each sample is 
tuariimicrobium , Bacillus , Brevibacterium , Campylobacter , Capnocytophaga , Cardiobac- 
ria , Peptoniphilus , Propionibacterium , Scardovia . B. Principal components analysis (i)
patient, respectively and (ii) Baseline, S2, and S3 samples. The first principle com- 
he plot indicates the similarity between bacterial communities with more similar
 principle component. C. Dendogram displaying the realtionship between the com- 
y-Curtis quantitative index of dissimilarity. Major clusters of individual community
icates the Bray-curtis dissimilarity score with scores closer to 1 indicating increas- 





































































e  of these taxa not only during stable and exacerbating periods but
also following antibiotic treatment, as has been shown by culture-
independent studies [ 7 ]. Furthermore, by completion of treatment,
lung function had increased compared to the previous study visit.
However, despite these changes, it was difficult to relate changes
in clinical state to shifts in the community structure due to inter-
patient variability ( Fig. 3 B), corroborating with previous findings
[ 8 ]. 
Given that differences in bacterial community stability were
observed between the longitudinal cohorts i.e. the within-patient
samples were less stable in the pulmonary exacerbation cohort
compared to the clinically stable cohort, we investigated, in an
additional analysis, if extended-quantitative culture could provide
prognostic information on the future risk of an exacerbation. Nei-
ther ecological indexes nor bacterial density predicted an exacer-
bation. However, the extended-quantitative culture measures in-
cluded may not provide enough taxonomic resolution to be clin-
ically informative e.g. the density of individual bacterial species
might be important. Further, exacerbations could be triggered by
viral infections, which were not tested for in this study. In contrast,
clinical parameters (lung function, BMI and respiratory symptom
score) were good predictors of a future exacerbation [ 22 , 25 , 26 ]. 
The bacterial genera reported here are typical of those detected
using culture-independent methods [ 5–7 ]. In keeping with earlier
findings, Prevotella and Veillonella were the most prevalent obligate
anaerobes cultured from sputum [ 9 , 10 ]. The role of anaerobes in
the CF airway remains contentious and might be affected by the
lack of resolution in classification of taxa. Anaerobes potentially
form part of a normal airway microbiota especially as they have
been identified in respiratory samples from healthy participants,
albeit at much lower TVC than in CF, and have been associated
with milder disease when dominant in the community [ 12 , 14 ]. In
contrast, there is also evidence that anaerobes contribute to a dys-
regulated inflammatory response or promote survival of recognised
pathogens and therefore, influence disease pathogenesis [ 27 , 28 ]. 
A limitation of this study is that a number of patients were
excluded from the longitudinal analyses ( Fig. 1 ) due to a lack of
e  xtended-quantitative culture data at all study visits and this con-
ributed to the small number of exacerbations studied; this re-
ects that some individuals were unable to expectorate any or
nly a small volume of sputum on some occasions. The majority
f patients, who were included in the longitudinal analyses, were
hronically infected with CF pathogens such as P. aeruginosa and B.
epacia complex and therefore, the findings may differ if the co-
ort included a larger number of patients without chronic airway
nfection. The duration of antibiotic treatment of an exacerbation
nd subsequent timing of the follow-up outpatient appointment
as variable in the pulmonary exacerbation cohort analysed and
ow this may impact the findings is unknown. Moreover, analy-
is of sputum samples cannot reveal whether airway communities
re spatially heterogeneous [ 30 ] or reflect whether an exacerba-
ion occurs due to extension of infection into less affected areas.
his inability to infer individual airway communities is a general
imitation of sputum in both clinical care and research. Although
here was no evidence of a universal signature of the lower airways
acterial community that predicted a future exacerbation, most of
he participants included were adults with infection with recog-
ised CF pathogens and all expectorated spontaneously indicating
ore advanced disease; therefore, findings may not extrapolate to
ounger populations [ 29 ]. It is also important to acknowledge that
 general constraint of a quantitative microbiology approach is fail-
re to detect viable but non-culturable bacteria. 
. Conclusions
In conclusion, extended-quantitative culture provides a detailed
ssessment of the viable lower airway bacterial community and
hows that community composition varied between patients. Con-
erved bacterial communities were more characteristic of those
ith stable disease over many months whilst exacerbations were
ssociated with a temporal fluctuation in bacterial density with an-
ibiotics and a greater change in community structure. Although
xtended-quantitative culture parameters were not prognostic of
xacerbations, it is unclear whether they could be used to track
Fig. 3. Pulmonary exacerbation cohort ( n = 7; hypothesis 2). A. Principal components analysis (i) individual patients, with different coloured points (samples) indicating 
the study visit or patient, respectively and (ii) Baseline, PEx1, PEx2 and Follow-up samples. The first principle component (PC1) accounts for most of the data variability.
The proximity of the points on the plot indicates the similarity between bacterial communities with more similar communities being closer together. Elipses indicate 95%
confidence intervals. PC2, second principle component. B. Dendogram displaying the realtionship between the community structure (bacterial membership [CFU/g]) of sputum
samples according to the Bray-Curtis quantitative index of dissimilarity. Major clusters of individual community structures are shown by different coloured boxes (labelled
1–6). Bifurcation of clusters indicates the Bray-curtis dissimilarity score with scores closer to 1 indicating increasing dissimilarity. Description of samples: Baseline, sputum
collected when clinically stable; PEx1, sputum collected at the initiation of treatment of a pulmonary exacerbation; PEx2, sputum collected at completion of treatment of a


































nd predict an individual’s disease progression or guide antimicro-
ial therapy. 
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